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Abstract
Most tumors are heterogeneous and many cancers contain small population of highly tumorigenic
and intrinsically drug resistant cancer stem cells (CSCs). Like normal stem cell, CSCs have ability
to self-renew and differentiate to other tumor cell types. They are believed to be a source for drug
resistance, tumor recurrence and metastasis. CSCs often overexpress drug efflux transporters,
spend most of their time in non-dividing G0 cell cycle state, and therefore, can escape the
conventional chemotherapies. Thus, targeting CSCs is essential for developing novel therapies to
prevent cancer relapse and emerging of drug resistance. Nanocarrier-based therapeutic agents
(nanomedicines) have been used to achieve longer circulation times, better stability and
bioavailability over current therapeutics. Recently, some groups have successfully applied
nanomedicines to target CSCs to eliminate the tumor and prevent its recurrence. These approaches
include 1) delivery of therapeutic agents (small molecules, siRNA, antibodies) that affect
embryonic signaling pathways implicated in self-renewal and differentiation in CSCs, 2)
inhibiting drug efflux transporters in an attempt to sensitize CSCs to therapy, 3) targeting
metabolism in CSCs through nanoformulated chemicals and field-responsive magnetic
nanoparticles and carbon nanotubes, and 4) disruption of multiple pathways in drug resistant cells
using combination of chemotherapeutic drugs with amphiphilic Pluronic block copolymers.
Despite clear progress of these studies the challenges of targeting CSCs by nanomedicines still
exist and leave plenty of room for improvement and development. This review summarizes
biological processes that are related to CSCs, overviews the current state of anti-CSCs therapies,
and discusses state-of-the-art nanomedicine approaches developed to kill CSCs.
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1. Introduction
Tumors are heterogeneous tissues with abundant phenotypically and functionally distinct
cell subpopulations each having different capacities to grow, differentiate, develop drug
resistance and form metastases [1]. In 1977, Hamburger and Salmon have shown that cancer
cells derived from multiple myeloma patients can be cloned in soft agar at a frequency of 1
clone for from 100 to 100,000 cells and hereby suggested that only a small portion of tumor
cells are tumorigenic [2]. These rare cells are now sometimes called “cancer stem cells”
(CSCs) as they share many characteristics with normal stem cells, such as self-renewal and
differentiation. A growing body of evidence suggests that CSCs can play a major role in
cancer initiation, progression, resistance, recurrence, and metastasis in selected cancers [1,
3–5]. CSCs are intrinsically drug resistant and often display same phenotypes as multidrug
resistant (MDR) cells including expression of drug efflux transporters [6], activation of anti-
apoptotic signaling pathways [7, 8], and reprogramming of metabolic processes [5].
Notably, treatment with most commonly used chemotherapeutic drugs often results in an
increase of the CSCs fraction in the tumor, making it more likely that these cells survive and
spread to distant sites (Table 1). Tumor relapses are often observed after the treatment with
those chemotherapies, which kill only the bulk of the more sensitive tumor cells, while
allowing more resistant CSCs to evade. As a result, CSCs can even constitute the greatest
fraction of the remaining/recurrent tumors (Fig. 1).
Based on these considerations chemotherapeutic approaches targeting CSCs may be more
successful in treating cancer. However, tumors display plasticity and therefore elimination
and targeting of CSCs without killing other cancer cells (non-CSCs) may not result in the
complete cure. It has been shown that CSC phenotype can be “dynamic” as under certain
conditions non-CSCs tumor cells can reverse their phenotype and become CSCs. Therefore
successful therapy must eliminate both the bulk tumor cells and rare CSCs (Fig. 1). Overall,
further preclinical and clinical studies are needed to definitively assess how CSCs respond to
therapy. The design of these studies should take into account diverse biomarkers of the
CSCs phenotypes and parameters of the CSCs function to provide robust clinical data on the
role of such cells in the disease progression and therapy.
Developing simple, effective and robust therapeutic strategies against CSCs is needed to
increase the efficacy of cancer therapy. Although some anti-cancer agents proposed recently
can efficiently kill CSCs, similar to other anticancer drugs, most such agents have
limitations upon translation into clinical studies, such as off-target effect, poor water
solubility, short circulation time, inconsistent stability, and unfavorable biodistribution.
Nanotechnology has shown significant promise in development of drugs and drug delivery
systems that can overcome such limitations and address urgent needs to improve efficacy of
diagnosis and therapy of various diseases [15, 16]. There is an increasing number of
nanoparticle-based carriers used in drug delivery systems (“nanocarriers”), such as
polymeric micelles [17–20], liposomes [21–23], dendrimers [24, 25], nanoemulsions [26],
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gold [27, 28] or metal nanoparticles [29], etc. (Fig. 2). Some nanocarrier-based therapeutic
products (also termed “nanomedicines”) are already on the market for treatment of cancer,
lipid regulation, multiple sclerosis, viral and fungal infections [30, 31] while others undergo
clinical and preclinical evaluation. Specifically, in the field of cancer therapy,
nanotechnology is applied to improve bioavailability and decrease systemic toxicity of anti-
cancer agents [32, 33]. Successful examples of clinically approved nanomedicines for cancer
therapy include liposomal doxorubicin Doxil®, albumin-bound paclitaxel Abraxane®, PEG-
L-Asparaginase Oncaspar® and others. Doxil®, the first polyethylene glycol (PEG) modified
(“PEGylated”) liposomal nanomedicine approved by the Food and Drug Administration
(FDA) exhibits more than 100 times longer blood circulation half-life than that of free drug
and decreases the risk of the cardio toxicity, which is a major side effect of the free drug
[34–36].
In the past two decades, examples of nanotechnology-based approaches to tackle the CSCs
problem have been accumulating [37, 38]. In general, nanoparticles were applied to target
CSCs in three broad and overlapping areas: 1) as “beacons” to label CSCs by their
biological signatures [39, 40]; 2) as nanocarriers to deliver “non-druggable” (for example
insoluble or unstable) anti-CSCs agents to CSCs [41, 42] and 3) as therapeutic modality on
its own to wipe out CSCs without harming normal, healthy stem cells [43–45]. Recently,
some groups have successfully applied nanomedicines to target the CSCs to eliminate the
tumor and prevent its recurrence. However, the challenges of targeting CSCs by
nanomedicines still exist and leave plenty of room for developing future therapies.
CSCs exhibit specific phenotypes that are different from other tumor cells, and can be
identified by the overexpression of certain biomarkers, such as, CD133+, CD44+CD24−,
aldehyde dehydrogenase (ALDH+) and many others. High expression levels of these
markers are associated with poor prognosis in patients [46, 47]. However, using these
markers to target anti-cancer agents to CSCs is associated with several pitfalls. First, the
markers differ from one type of cancer to another and there is no universal marker that can
be used for all cancers [48, 49]. Second, multiple pools of biologically distinct CSCs can
exist within one tumor as was shown both for acute myeloid leukemia [50, 51], as well as
solid tumors [52]. Finally, CSCs share the markers’ expression profiles with normal stem
cells and therefore, there is a risk of affecting normal stem cells when targeting
chemotherapeutic drug to CSCs. Moreover, since the CSCs phenotype is not a stable trait
killing only the CSCs may not be sufficient for eliminating the tumors.
Thus, development of successful therapeutic modalities that can kill CSCs will require a
comprehensive understanding of the characteristics of CSCs and relevant mechanisms (Fig.
1) as well as applying modern technologies for drug delivery. In this review we will
summarize particular biological processes that are related to CSCs, and overview specific
nanomedicine-based therapeutic approaches to ascertain the key question: can
nanomedicines make difference in killing CSCs?
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2. Cancer cell heterogeneity and its implications for therapy
2.1 CSCs vs. clonal evolution hypothesis
There is an overwhelming body of evidence suggesting that similar to normal tissues,
tumors are comprised of heterogeneous cell populations with varying metastatic potential
[53–55], angiogenic potential [56] and drug resistance [57, 58]. M. Gerlinger and colleagues
studied the tumor heterogeneity from multiple regions within a single patient’s tumor by
exome sequencing, chromosome aberration analysis, and ploidy profiling. They observed
that about 63–69 % of the mutations found in single biopsies were not uniformly detectable
throughout all the regions of the same patient’s tumor, which provides clear evidence of
tumor heterogeneity and the importance of the multi-region biopsy in cancer diagnosis [59,
60]. However, multi-region biopsy is always limited to the tumors and tumor cells with
known and accessible physical location(s). Therefore, an alternative to multi-region biopsy
so-called “liquid biopsies” has been developed, which uses single cell profiling of
circulating tumor cells (CTCs) from patients’ blood by microfluidics-based single cell
transcriptional profiling technology [61]. Using this approach Powell and colleagues have
identified 87 cancer-associated and reference genes among individual CTCs, which indicates
the heterogeneity in the CTCs [61]. Moreover, Rottenberg and colleagues transplanted
different parts of original mammary tumor into new host animals and found that these new
tumor grafts responded differently to same treatments, displaying variability in times until
relapse or rates of tumor growth [57, 62].
While the phenomenon of tumor heterogeneity is frequently observed, the cause of the
heterogeneity among the tumor cells is not fully understood and still debated. Partly this is
due to incomplete knowledge about cell-of-origin in cancer and factors underlying tumor
progression that may vary from one tumor type to another. Still, among all the hypotheses,
the theory of CSCs has gradually gained wide acceptance and influenced all approaches to
cancer research and therapy [63]. The CSCs hypothesis postulates a hierarchical
organization of tumor cells such that only a small population of cancer cells is responsible
for sustaining tumorigenesis and establishing the cellular heterogeneity in the primary tumor
[64]. At the top of this hierarchy are the CSCs with unlimited dividing ability, that give rise
to more differentiated progenies, which are only able to divide certain number of times.
CSCs are phenotypically distinct from other tumor cells, which enables their identification
using fluorescence-activated cell sorting (FACS). A number of markers have been proven
useful for the identification of CSCs in multiple types of leukemia and solid tumors,
including CD34, CD133, CD44, epithelial cell adhesion molecule (EpCAM), breast cancer
resistance protein (BCRP) and aldehyde dehydrogenase-1 (ALDH1) activity. However, in
different types of cancer different molecules may serve as “stem cell markers”, and none of
these markers can be used exclusively to isolate CSCs in every type of tumor. This greatly
complicates the CSCs studies. Furthermore, even using the same type of tumor, the same
cell line, and the same CSCs marker, the portion of CSCs reported by different laboratories
can be dramatically different. For instance, the ALDH% in SUM159 cells from Dr.
Woodward’s report is as high as 61.5% [65], while, in Dr. Arteaga’s study, the portion of
ALDH% in SUM159 is less than 2% [66]. Therefore, CSCs markers alone may not be
sufficiently specific to identify CSCs in different tumors. To overcome these limitations, a
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combination of markers has to be used for better isolation and identification of CSCs [67].
However, so far no “perfect” combination of markers has been confirmed to successfully
identify CSCs [68]. Similar to normal stem cells, CSCs are capable of self-renewal and
differentiation. With the first property, the stem cell has potential to give rise to the new
stem cell without differentiating into different cell types. Generally, self-renewal is the
process by which stem cells divide to make more stem cells (symmetric division) [69]. With
the second property, CSCs can divide and give rise to two distinct cell types – one a copy of
the original stem cell and the other a progenitor cell that can differentiate into different cell
types after amplification (asymmetric division). It is however characteristic for CSCs to
mainly exist in a quiescent non-cycling G0 state [5, 58]. This makes them significantly less
susceptible to chemotherapeutic drugs that kill actively dividing cells [70].
Despite general acceptance of the CSCs model, the question remains which cancers out of
the vast variety do actually follow this model? The CSC model was not confirmed for all
cancers and was really only tested in a limited number of tumors [71]. It is important to note,
that methods used to study the CSCs are rather limited. For example, in vivo cell
transplantation to immunocompromised mice, which is widely used to study tumorigenicity
and to estimate frequencies of tumorigenic cells can severely underestimate the real
frequency of tumorigenic cells and results can significantly differ depending on the strain of
mice used [72]. In particular, transplantation of melanoma cells into extremely
immunocompromised NOD/SCID interleukin-2 receptor gamma chain null (Il2rg(−/−))
mice has shown the frequency of tumorigenic cells to be several orders of magnitude higher
compared to the results observed in NOD/SCID mice [72]. Moreover, the ability of a cancer
cell to form a tumor does not mean by default that it is a stem cell. To qualify, the cell
should possess other properties, like drug resistance, specific phenotype, etc. Finally, as
mentioned above, one should be very careful using certain markers for CSCs
characterization in various tumors since CSCs markers lack specificity and greatly vary
between different types of cancers.
For certain cancers no distinct cell subpopulation(s) that can be attributed to CSCs was
identified so far using existing methodologies. For instance, in a well established engineered
mammary tumor mouse model, MMTV–Erbb2 no CSCs subset could be identified using
various cell surface markers [73–75]. The heterogeneity and tumor progression in such cases
is better explained by a classic “clonal evolution” model, which assumes that tumor
heterogeneity is a result of stochastic genetic and/or epigenetic changes in cancer cells and
that each cell has a chance to become tumorigenic and/or drug resistant if it accumulates
sufficient genetic/epigenetic changes (Fig. 3A). This clone in turn generates phenotypically
similar cells with different but close tumorigenic potential without any hierarchy. Moreover,
identification of CSCs markers in melanoma to date remains challenging. In vivo cell
transplantation experiments have shown that very high portion of melanoma cells are
tumorigenic (at least 25%) [4, 72] and that these cells produce tumors without any hierarchy.
Morrison et al. showed that melanomas from patients have common and phenotypically
diverse tumorigenic cells that undergo reversible phenotypic changes and not hierarchically
organized in vivo [75]. Even though slow-cycling JARID1B-expressing melanoma cells that
are required for continuous tumor growth in vivo were recently identified, these cells do not
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follow the classical CSCs non-stem cells convert to stem cells was observed for other
cancers as well as normal stem cells [77]. This behavior is explained within a so-called
“dynamic CSCs model” (Fig. 3B). According to this model CSCs phenotype is much less
stable compared to classic CSCs model and non-CSCs can acquire tumorigenicity due to
effect of specific microenvironment and/or through genetic/epigenetic changes [49, 64, 78].
Importantly one should be cautious in assigning just one model described above to a certain
cancer, as all the models are not mutually exclusive. Thus, in the hierarchically organized
cancers the clonal evolution can still occur in CSCs and/or non-CSCs. Therefore, while
designing an efficacious and comprehensive cancer treatment strategy one should consider a
need for eliminating the CSCs, the non-CSCs as well as impairing the specialized
microenvironment housing the CSCs (known as “niche”) (Table 2).
2.2 Drug efflux transporters and drug resistance in CSCs
A very important characteristic of CSCs is the expression of high levels of ATP binding
cassette (ABC) transporters (Table 3). Expression of such transporters is commonly
associated with MDR as they provide for a unique defense of cells against chemotherapeutic
drugs by significantly decreasing the cellular accumulation of cytotoxic agents. (Notably,
CSCs are quiescent [70], they spend most of their time in G0 cell cycle phase [81], and have
high DNA repair capacity [82], which is believed to be an additional reason for their
chemoresistance.) The classic theory of MDR development posits that MDR cells may
repopulate the tumor after the therapy as a result of selection when some of the cancer cells
accumulate necessary genetic and/or epigenetic changes that confer drug resistance (Fig.
4A). Such resistant cells acquire selective advantage over the rest of the cells, which allows
them to evade the therapy. According to the CSCs theory, tumors already contain small
population of intrinsically resistant tumor initiating cells, which similar to normal stem cells
overexpress drug efflux transporters, while their more differentiated progenies loose this
property. For example, hematopoietic stem cells overexpress ABCG2, while their
differentiated progenies do not [83]. Exposure to the chemotherapeutic drugs eliminates the
drug sensitive stromal tumor cells, leaving the CSCs. Mutations in the surviving CSCs and
their progenies can lead to the development of MDR phenotype (Fig. 4B).
Historically, investigators noticed that a fluorescent vital cell dye Hoechst 33342, which is
used to study the cell cycle, could be also used to isolate stem cells [84, 85]. Stem cells are
Hoechst dim due to overexpression of the BCRP (ABCG2) drug efflux transporter, which
pumps this dye out of the cells. Goodell et al. have demonstrated that display of Hoechst
33342 fluorescence in bone marrow cells (at red and blue emission wavelengths
simultaneously) allows distinguishing a small subpopulation of Hoechst dim cells with
phenotypic markers of multipotent hematopoietic stem cells. This small subset of cells
named “Side Population” was at least 1,000-fold enriched with cells that are capable for
repopulation of bone marrow of lethally irradiated mice [86]. From then on, Hoechst 33342
exclusion assay has been performed in many laboratories, and the cells located within the
side population have consistently shown CSCs-like properties in many types of tumors, such
as breast [84], lung [87], brain [88], pancreatic [89] and others. For example, Yin et al.
reported that purified MCF7 side population cells with ABCG2 gene expression that are
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more resistant to ABCG2 substrate, mitoxantrone compared to non-side population cells
also have an increased ability to colonize the mouse mammary gland [90]. Inhibition of
ABCG2 transporter using low molecular weight inhibitors has been investigated as one of
the strategies to sensitize and kill CSCs for more effective therapy. Several inhibitors of
ABCG2, including fumitremorgin C (FTC) [91, 92], tryprostatin A [93, 94], tariquidar [95],
etc. have been explored. However, toxicities of these compounds to healthy cells observed
in in vitro and in vivo hindered their development in clinical studies. Using a novel ABCG2
inhibitor, a non-toxic FTC analogue KO143 resulted in increased intracellular mitoxantrone
accumulation in CD34+CD38− CSCs in the majority of AML patients [96] (Table 3), albeit
the clinical benefit of this compound for treatment of cancer remains to be seen. It has been
shown recently, that silencing of adenine nucleotide translocator-2 (ANT2), which is
involved in glycolytic metabolism and is overexpressed by undifferentiated proliferating
cells and CSCs [97] using adenovirus encoding ANT2 shRNA could effectively induce
apoptosis in breast CSCs and sensitize these cells to doxorubicin via downregulation of
ABCG2 transporter [97].
Drug resistance of CSCs has been also associated with overexpression of other drug efflux
transporters. For example, P-glycoprotein (Pgp), also designated ABCB1, is one of the most
important efflux transporters related to CSCs resistance. Studies have shown that higher
expression of CD133 in CSCs or transfected cells was accompanied with an elevated
ABCB1 efflux activity. For example, Angeastro et al. found that Pgp/ABCB1 was
upregulated and displayed functional drug efflux activity in 62% of CD133+ glioma cells in
comparison with the parental cells [98]. The mechanism behind the increase in transporter
expression and activity in CSCs is not clear, however, recent study pointed out that cisplatin
treatment selects for MDR CD133+ cells by activating Notch signaling pathway [10].
Treatment of lung cancer cells with low doses of cisplatin enriched CD133+ cells and
upregulated ABCG2 and ABCB1 transporters expression in these cells. These effects were
also mediated through the Notch signaling pathway, as the co-administration of the Notch
signaling inhibitor remarkably reduced levels of CD133, and increased the sensitivity of
tumors to the chemotherapy [10].
Pgp cousin, ABCB5 is another ABC transporter implicated in the drug resistance in CSCs in
different tumor types. For example, Frank and colleagues noted that ABCB5 can serve as
biomarker for purification and characterization of adult skin-associated stem cells, while
also functioning as a MDR transporter and conferring resistance to chemotherapy in vitro in
human malignant melanoma [99–101]. ABCB5 was found to be specifically expressed on
CD133+ melanoma cells [102]. Monoclonal antibodies (mAb) against ABCB5 were also
shown to sensitize melanoma cells to anti-cancer drug, doxorubicin [100]. Therefore
ABCB5 inhibition may represent an attractive strategy for the development of new
melanoma therapies.
Even though MDR has been known for over 30 years (since discovery of Pgp in 1976) the
success in overcoming it clinically is rather limited. Several strategies were proposed to
overcome drug resistance [103–106]. Much effort has been devoted to development of new
cytotoxic drugs and the use of combination chemotherapy regimens to improve cure rates.
Unfortunately these strategies have produced only limited success in MDR tumors [107].
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Dose-intensified and high-dose regimens are active in certain cases, however treatment-
related morbidity and mortality are usually high [103, 107]. Thus, alternative strategies
using chemosensitizing agents to amplify drug activity in resistant tumors have been
evaluated in both laboratory and clinical investigations [106, 108]. Since the 1990’s a
variety of agents that inhibit drug efflux transporters have been attempted in clinical studies
in different cancers. Initial studies have focused on agents, which inhibit the Pgp efflux
pump. Several generations of such Pgp-modulating agents have been developed and tested
in clinical trials [58, 105, 109]. The first generation of MDR reversal agents, such as
cyclosporine A and verapamil had relatively low affinity to Pgp and their use was limited by
unacceptable toxicity and low tolerability. The more potent and less toxic agents of the
second generation (valspodar, biricodar and others) have shown some success but they also
affected non-targeted proteins and failed due to the unpredictable pharmacokinetic
interactions. Notably some of these agents inhibited cytochrome P450, and this resulted in
increased drug levels in the blood and the risk of drug overexposure [109]. The even more
potent and specific third generation agents were expected to have less effect on drug
pharmacokinetics [105, 106] and are currently in clinical trials. But some of these trials have
already reported negative results and study design issues, regarding either dosing regiments
or patient selection [110]. Overall, targeting of ABC transporters with low molecular weight
inhibitors have not been very successful in overcoming general MDR in cancers, and
therefore, it is likely that in the case of CSCs this approach at present stage will not prove
effective. Thus, broad-spectrum inhibition, rather than modulation of single mechanisms, is
likely to be required to circumvent drug resistance and eradicate CSCs. As was mentioned
above, there have been attempts to directly (using low molecular weight inhibitors or mAb)
or indirectly (inhibition of cell signaling pathways or regulatory RNA, etc.) target ABC
transporters in CSCs, however, the number of reports using ABC transporters as a target for
CSCs therapy is rather limited. Possibilities of using polymer therapeutics and polymeric
nanocarriers to circumvent drug resistance of CSCs are discussed in Section 3 below.
2.3 Abnormal cellular metabolism in CSCs
It is known that the mitochondrial metabolism in normal stem cells is different from that in
differentiated cells [120, 121]. Stem cells are characterized with higher rate of glycolysis,
higher amount of ATP/cell and more pronounced perinuclear localization of mitochondria
[120]. Moreover, the integrity and function of mitochondria are important for life span,
differentiation, and overall maintenance of the stem cells [120, 121]. Similar to normal stem
cells the CSCs display different metabolism compared to the rest of the tumor cells. For
example, the mitochondrial membrane potential within a tumor mass is heterogeneous and
these differences can be used as a tool to identify, isolate and enrich CSCs populations
[122]. Specific properties of lung CSCs, that distinguish them from the bulk tumor cells
have also been described, such as low quantity of mtDNA, high mitochondria membrane
potential, low oxygen and glucose consumption, and a low intracellular concentration of
ATP and reactive oxygen species (ROS) [122].
Recently, Lagadinou and colleagues reported that leukemia CSCs have lower rate of energy
metabolism and lower cellular oxidative status (termed “ROS-low”) compared to non-CSCs
[123]. These authors have also shown that ROS-low leukemia CSCs aberrantly express
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BCL-2, which provides a potential targeting strategy for CSCs therapy. Similar observation
was made in the glioma stem cells (GSCs). Vlashi and colleagues evaluated the metabolic
state of GSCs and compared basal oxygen consumption rates and extracellular acidification
rates in differentiated tumor cells and GSCs derived from tumorspheres [124]. They found
that GSCs consumed less glucose, produced less lactate, and had higher ATP levels
compared to their differentiated counterparts. Interestingly, GSCs tolerated very well the
inhibition of either glycolysis or mitochondrial respiration, and only simultaneous inhibition
of both metabolic pathways induced significant ATP depletion, indicating that GSCs utilize
multiple pathways to produce energy [124]. Notably, the ability of GSCs to tolerate
oxidative stress was different in different cell lines and correlated with the intrinsic
radioresistance of GSCs. In other studies a direct correlation between mitochondria
membrane potential and tumorigenicity was found [125]. Specifically, the cells with higher
mitochondria membrane potential also had higher tumorigenicity while depletion of the
membrane potential in those cells with rapamycin significantly decreased their
tumorigenicity [125]. In conclusion targeting tumor metabolism and reprogramming it to the
“normal” status can potentially impair growth of CSCs, induce differentiation of CSCs and
finally sensitize CSCs to the therapy. Some applications of nanomedicines in this direction
are discussed below in Section 3.4.
2.4 Embryonic signaling pathways in CSCs
It is widely accepted that tumors often develop and progress due to deregulated self-renewal
pathways. During the last decade, a better understanding of these aberrant signaling
pathways allowed to propose new therapeutic strategies aiming to suppress the tumor
regrowth. Specifically, Wnt, Notch, and Hedgehog embryonic signaling pathways have been
implicated in self-renewal and differentiation in CSCs in many types of cancer [126, 127].
These signaling pathways related to CSCs are of interest as potential targets for therapeutics
development [126]. Several therapeutic agents and cell-based therapeutics targeting these
signaling pathways have reached various stages of clinical trials (Table 4).
For example, Wnt/β-catenin signaling pathway was shown to play a pivotal role in the
maintenance of tissue homeostasis by regulating self-renewal of normal stem cells as well as
proliferation or differentiation of progenitor (transit-amplifying) cells in embryogenesis [8,
128]. The β-catenin is a transcription factor, which in un-activated cells is phosphorylated
and localized in the cytoplasm. Upon activation of the Wnt signaling the β-catenin becomes
dephosphorylated and translocates into the nucleus where it activates the target genes [129].
Chronic upregulation of Wnt signaling was observed in several cancers and appears to play
an important role in CSCs [8]. This pathway is involved in malignant transformation, and
associated with tumor aggressiveness, metastases and poor clinical outcome [130–132]. One
example of therapeutic agent targeting the Wnt/β-catenin pathway is PRI-724, a specific
small molecule CREB-binding protein (CBP)/β-catenin antagonist, which is in Phase I and
II clinical trials in patients with acute myeloid leukemia (AML), chronic myeloid leukemia
(CML), pancreatic cancer and advanced solid tumors [133]. Another example is
Vantictumab (OMP-18R5) a mAb that interacts with the extracellular domain of 5 Frizzled
receptors (1, 2, 5, 7, 8) and blocks canonical Wnt signaling [134]. Preclinical xenograft
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studies have shown OMP-18R5 inhibits tumor growth, reduces tumor-initiating cell
frequency and exhibits synergistic activity with conventional therapy [134].
Notch signaling pathway is one of the most intensively studied putative therapeutic targets
in CSCs. Notch as well as most of its ligands are transmembrane proteins, and therefore
Notch pathway is usually activated through a direct cell-cell contact. Upon ligand–receptor
binding the Notch receptor undergoes a conformational change that exposes previously
protected sites to proteolytic cleavage by metalloprotease and γ-secretase and results in
release of extracellular and intracellular fragments [126]. Interestingly, Notch signaling
pathway appears to play some role in drug resistance. Thus the side population isolated from
breast adenocarcinoma cells MCF7 overexpress Notch protein [135]. The down-regulation
of Notch expression enhances drug sensitivity of the cancer cells, inhibits tumor regrowth
and reduces migration and invasion of cancer cells. Inhibition of γ-secretase-mediated Notch
cleavage is a primary focus for the development of Notch pathway targeting therapeutics
[136]. For example, a phase I clinical trial (NCT00100152) evaluated a small molecule γ-
secretase inhibitor, MK-0752 in relapsed or refractory T-cell acute lymphoblastic leukemia
(T-ALL) and advanced breast cancer patients [137]. The Phase I/II Study of MK-0752
followed by docetaxel in advanced or metastatic breast cancer has been also completed
(Table 4). OncoMed Pharmaceuticals, Inc. has been developing several mAb-based
therapeutic agents that target Notch signaling pathway (Table 4). For example, Demcizumab
(OMP-21M18) is a humanized mAb against Delta-like ligand 4 (DLL4) in the Notch
pathway that inhibits CSCs growth and promotes cell differentiation. It has shown broad-
spectrum activity in pancreatic [138], breast and colon tumors [139]. In combination with
standard chemotherapy OMP-21M18 is currently in Phase I studies in patients with non-
squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer and pancreatic
cancer (Table 4). Another agent believed to target CSCs is OMP-52M51, a humanized mAb
against the cell surface Notch 1 receptor, which is currently evaluated in Phase I studies for
patients with relapsed or refractory lymphoid malignancies and solid tumors. OMP-59R5 is
a humanized mAb screened against Notch2 that binds both the Notch2 and Notch3
receptors. This agent is capable of downregulating the Notch pathway signaling and
affecting pericytes, hereby impacting stromal and tumor microenvironment. Currently,
OMP-59R5 is evaluated in Phase 1 dose escalation study in patients with previously treated
solid tumors, for which there is no remaining standard curative therapy and no therapy with
a demonstrated survival benefit. Additionally, two Phase Ib/II studies of 1) OMP-59R5 in
combination with Nab-paclitaxel (Abraxane) and gemcitabine in subjects with previously
untreated stage IV pancreatic cancer (“ALPINE”), and 2) OMP-59R5 in combination with
cisplatin and etoposide in patients with small cell lung carcinoma (SCLC) (“PINNACLE”)
are recruiting participants.
Hedgehog (Hh) signaling pathway has also been recognized as one of the most important
pathways in control of the patterning maintenance, tissue polarity, and stem-cell
maintenance during stem cell and embryonic development. The Hh pathway receptor,
Patched (Ptch1), in un-activated state actively suppresses the activity of a G-protein coupled
receptor-like protein, called Smoothened (SMO). In mammals three ligands, Sonic Hh
(SHh), Desert Hh (DHh), and Indian Hh (IHh) can activate the Hh pathway. Binding of one
of these ligands to Ptch1 receptor releases the inhibition of SMO, what leads to downstream
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activation of three transcription factors Gli1, Gli2 and/or Gli3 [140, 141]. Deregulation of
this pathway leads to tumorigenesis and metastasis [142]. It was first discovered in Gorlin
syndrome patients, which have somatic mutations in Ptch1 gene and develop multiple basal
cell carcinomas (BCCs) in their lifetime [143, 144]. Activating and inhibiting mutations in
Hh have been later reported in other BCCs and medulloblastoma [72, 145–147]. Recent
studies suggest that Hh signaling regulates CSCs in human cancers including pancreatic
cancer, breast cancer, multiple myeloma, glioblastoma and CML [7, 87, 148–151]. Several
Hh inhibitors were identified in recent studies (Table 4). For example, Vismodegib
(GDC-0449) a small molecule inhibitor of SMO decreased cell viability and induced
apoptosis in pancreatic CSCs [152]. This agent is now evaluated in combination with
gemcitabine in a pilot study treating patients with advanced pancreatic cancer. Another
example is BMS-833923 (XL139), an oral small molecule inhibitor of SMO capable of
inhibiting the expression of downstream effectors in the Hh pathway (Gli1 and Ptch1),
shown to reduce clone formation and fraction of ALDH+ CSCs [153, 154]. BMS-833923
has been evaluated as a single agent in Phase I trial in patients with advanced or metastatic
cancers, as well as in combination with other agents such as an ongoing Phase II study of
BMS-833923 in combination with Dasatinib (BMS-354825) in newly diagnosed Chronic
Phase (CP) CML subjects.
Other than Wnt, Notch, and Hh embryonic signaling pathways, Focal Adhesion Kinase
(FAK), a cytoplasmic tyrosine kinase that mediated signal transduction by integrins and
growth factor receptors also plays an important role in the tumor initiating capability of
CSCs [155]. There are two small molecule drugs, VS-6063 and VS-4718, which target FAK
signaling pathways and inhibit CSCs that are currently in early stages of clinical
development (Table 4). The first one is evaluated as a single agent in malignant pleural
mesothelioma and in combination with paclitaxel in patients with advanced ovarian cancer.
The second one is evaluated in metastatic non-hematologic malignancies.
In addition to the new therapeutic agents some currently approved drugs have also shown
ability to affect embryonic signaling pathways and displayed activity against CSCs. For
example, mAb-based anticancer drug, Trastuzumab (Herceptin) has shown ability to
decrease subpopulation of CD90+ cells in gastric cancer [156] and suppress tumorsphere
formation in breast cancer [157]. The studies suggest that this antibody affects ERBB2
signaling [156] and inhibits Notch1 signaling [157] in cancer cells. Trastuzumab was also
recently evaluated in combination with the Natural Killer (NK) cells to develop therapeutic
modality against breast cancer [158]. This work demonstrated the depletion of the CD44high/
CD24low/HER2low cells and antibody-dependent NK cells–mediated cytotoxicity (ADCC)
in breast cancer model [158]. Altogether new therapeutic agents and current drugs that target
embryonic signaling pathways in CSCs alone and in combination with other existing and
novel anti-cancer modalities have shown great promise in treatment of cancer.
2.5 Use of natural compounds and repurposing of existing drugs to treat CSCs
In attempts of developing anti-CSCs therapies some investigators explored effects of natural
compounds and nutraceuticals (Table 5). For instance, Li et al. reported that sulforaphane, a
dietary component of brocconi/broccoli sprouts, can decrease fraction of ALDH+ cells by
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65% to 80% (from 3.01% to 1.47% or 0.49%) in human breast cancer SUM 159 cell line
[45]. Sulforaphane was shown to prevent NF-kappaB binding, downregulate apoptosis
inhibitors and induce apoptosis, along with preventing clonogenicity in pancreatic CSCs
[159]. It was also shown to potentiate the efficacy of imatinib against chronic leukemia
CSCs through enhanced abrogation of Wnt/β-catenin function [160]. A pilot study will
determine whether broccoli sprouts rich in sulforaphane and quercetin as nutritional
supplement can positively affect the overall survival of surgically non-treatable patients with
pancreatic ductal adenocarcinoma that receive conventional cytoreductive (radio-)
chemotherapy (NCT01879878). Another example of nutraceutical with anti-CSCs activity is
curcumin and its analogues contained in Indian spice turmeric. One analog GO-Y030 was
shown to decrease phosphorylation of the signal transducer and activator of transcription 3
(STAT3), cell viability and tumorsphere formation in ALDH+ and CD133+ colon CSCs
[161]. Curcumin separately and in combination with another black pepper derived
compound an alkaloid piperine have shown to inhibit the tumorsphere formation, serial
passaging, and fraction of ALDH+ cells in normal and malignant breast cells [162]. These
compounds were also inhibiting the Wnt signaling pathway and suppressing breast stem
cells self-renewal but did not cause toxicity to differentiated cells. Other study suggested
that curcumin induced cell death in esophageal cancer cells through modulating Notch
signaling. Altogether, these studies suggest that select nutraceuticals could serve as potential
cancer preventive agents.
Along with nutraceuticals some well known drugs that were not originally intended for
cancer use has shown considerable anti-CSCs activity (Table 5). For example, metformin, a
first-line drug for type II diabetes has been reported to selectively target CSCs with
CD44+CD24− phenotype in breast cancer [163]. Based on this finding the effects of
metformin on CSCs are evaluated in clinical trial in patients with colorectal cancer
(NCT01440127). Moreover, metformin is evaluated in combination with standard systemic
chemotherapy in relapsed ALL that has a dismal outcome (NCT01324180) as well as with
chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer
(NCT01579812).
Silencing of E-cadherin using shRNA produces stabilized mesenchymal-like state that
captures many CSCs properties and provides novel model for CSC therapy screening [9,
164]. Using this method salinomycin, an antibacterial drug was selected via high-throughput
screening as a potential anti-CSCs agent that can kill CSCs 100 times more effectively than
the anti-cancer drug paclitaxel [9]. It reduced the CD44highCD24−/low cell portion and
decreased the tumorigenicity and lung metastases in vivo in breast cancer model [9].
Unfortunately, severe toxicity prevented the translation of salinomycin to the clinic for
human cancer patients, however, this example presents another case of repurposing the
existing drugs for anti-cancer therapy.
The search for the “old” drugs that can be repurposed for the new function of cancer
treatment or prevention based on their anti-CSCs activity continues. For example, in a
surprising finding upon screening a library of known compounds an antipsychotic drug
thioridazine was shown to selectively target the neoplastic cells and impair the human
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somatic CSCs capable of in vivo leukemic disease initiation, while having no effect on
normal blood stem cells [165].
These nutraceuticals and repurposed drugs that have shown anti-CSCs activity are
summarized in Table 5. Like regular chemotherapeutic drugs many of them are hydrophobic
and poorly soluble and/or have other problems after administration to the body such as poor
absorption, rapid metabolism, fast systemic elimination and low plasma stability, which
results in poor systemic bioavailability. Furthermore, as many of the anti-CSCs agents are
“old” drugs that have been used for treatment of other diseases, potential side effects (for
instance, neural and muscular toxicity of salinomycin [166], lactic acidosis of metformin
[167] etc.) limits advancement of these agents to clinics.
2.6 CSCs niche
The niche is specialized microenvironment housing the stem cells that is essential for their
life and function [180, 181]. The niche regulates stem cells’ capacity to self-renew and
differentiate and prevents stem cells from depletion [182]. It is a complex environment and
includes various types of cells, such as immune and mesenchymal cells, extracellular matrix
and vascular network. Extensive research implies that CSCs also reside in a specific niche
that controls their differentiation, proliferation and self-renewal [73, 183, 184]. Notably,
CSCs can also be generated by the microenvironment through induction of CSCs features in
more differentiated tumor cells [185]. Therefore, CSCs niche represent a potential target for
cancer therapy, although it is not sufficiently well studied and its role in cancer is still being
debated [186].
2.7 CSC isolation and characterization methods
As discussed above CSCs are functionally and phenotypically distinct from other tumor
cells. Based on these properties a number of assays have been developed to isolate/
characterize the CSCs. This section describes some of the main methods used to study
CSCs. The self-renewal and lineage capacity are fundamental properties of any stem cell.
Thus, CSCs can also be identified by their ability to self-renew, as well as form and
propagate tumors [144]. Therefore, the first functional approach used to study CSCs is serial
transplantation into immunocompromised (typically NOD/SCID) mice. It was initially
designed to study normal stem cells, specifically hematopoietic stem cells. In this assay the
cells are orthotopically transplanted into immunocompromised mice and mice are observed
for tumor formation over certain period of time. Moreover, the frequency of tumor initiating
cells in the sample can be estimated using a series of limiting dilution transplantations [145,
146, 187]. For this purpose graded dilutions of cells are transplanted into mice, and the
animals are further observed for tumor formation. The extent of the cell dilution should vary
from sufficiently low to ensure that each mouse within a group develops tumors (positive
response) to sufficiently high to ensure that the positive response is observed very rarely.
The response can be quantified as a function of the dose of the transplanted cells. In this
approach the tumor initiating cell frequency is determined from the semi-logarithmic plot of
fraction of negative responses as a function of cell dose, and corresponds to the cell dilution,
which produces 37% of negative responses. The analysis is carried out under assumption
that only one tumor initiating cell is sufficient to produce the tumor and that other cancer
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cells are present in excess (for more detailed information and its limitations please refer to
[146]). To evaluate self-renewal, the tumor cells are isolated and transplanted into new host
animal. The ability to form serially transplantable tumors suggests a capacity for self-
renewal while the number of serial transplants can serve as a measure of self-renewal
potential [147]. This method is considered a “gold standard” to demonstrate two major
properties of stem cells (i.e. the ability to recapitulate the original tumor and self-renew), but
it also has some major disadvantages. On the one hand, orthotropic cell transplantation
simulates the organ-of-origin microenvironment, but on the other hand, the effect of
microenvironment is very complex and can significantly alter the results. Therefore, the
strain of the mice used for the assay can strongly affect the result and tumor initiating cell
frequencies can be drastically differ for different mice strains [72]. This approach has also
some technical shortcomings and limitations. For instance, the use of Matrigel® for in vivo
serial transplantations may affect tumor formation and thus alter the “apparent” frequency of
tumor initiating cells. Additionally, preparation of viable single-cell suspensions can be
challenging for solid tumors and may accidentally lead to a loss of the CSCs populations.
The second functional approach to CSCs isolation and characterization involves in vitro
anchorage-independent growth and colony-forming unit (CFU) assay. This approach is
considered a surrogate for in vivo transplantation and is fast, quantitative and high-
throughput. Briefly, culturing CSCs under non-adhesive conditions (ultra-low attachment
culture system) in serum-free medium supplemented with adequate growth factors and
cultured can produce so-called “tumorspheres” [188]. Regular tumor cells in these
conditions undergo “anoikis”, a suspension-induced apoptosis, while CSCs survive and form
three-dimensional tumorspheres on the one cell-one sphere (colony) basis. Moreover
culturing in suspension encourages the display of the CSCs properties, and thus, the
resulting tumorspheres contain higher portions of CSCs than the parental tumor cells [189].
Similar to in vivo limiting dilution assay, the frequency of tumor initiating cells, or colony-
forming units, can be determined using in vitro limiting dilution. It should be noted
however, that these in vitro and in vivo assays are not self-excluding, but rather
complementary to each other. Low cost and high throughput capacity of the in vitro assay
makes it very convenient for screening, but the results should be ultimately confirmed by a
regular in vivo serial transplantation assay.
The third functional method for isolating CSCs is based on overexpression by these cells of
drug efflux transporters, specifically BCRP. We have discussed above that Hoechst 33342
excluding side populations were shown to maintain CSCs properties in many types of
cancers and currently this method is widely used to isolate CSCs [87, 148, 149].
The phenotypic method for CSCs isolation by flow cytometry using fluorescently labeled
antibodies that target distinct phenotypes of CSCs. Over past several years numerous CSCs
markers and their combinations have been identified in many cancers as described above.
However, since the marker specificity varies from one type of cancer to another and even
within the same tumor such markers may not be exclusive to CSCs, one should be very
careful in using such markers for CSCs isolation and characterization. In this regard using a
combination of two or more markers in CSCs analysis is always recommended. Moreover,
any analysis using CSCs surface markers must be supplemented with one or several
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functional assays described above to validate the self-renewal and tumor initiating capacity
of the cells with identified phenotype.
Finally, increased activity of cytoplasmic enzyme aldehyde dehydrogenase-1 (ALDH-1) has
been reported to be characteristic for CSCs in many cancers [150, 151, 190]. Based on this
property an assay has been developed using ALDH substrate, which becomes highly
fluorescent after enzymatic transformation. As a result, the ALDH-overexpressing cells can
be identified and sorted by flow cytometry. However, similar to other phenotype-based
sorting assays, the identified cells must to be functionally characterized to confirm their
stem cell-like properties.
Overall, a good set of tools to study CSCs is currently available. Various in vitro assays
must be used in combination and while they can be very useful in the beginning of the study
due to low cost and efficiency, the results have to be carefully validated in vivo.
2.8 Summary of molecular and cellular targets for CSCs therapeutics development
As mentioned before, many researchers agree that the truly curative therapies should target
both CSCs and non-CSCs [1, 49]. A lot of effort has recently been put towards developing
anti-CSCs therapies. There are several drugs in clinical trials, and many more in preclinical
development that are designed to specifically eliminate or suppress CSCs. The possible
therapeutic approaches to kill CSCs are summarized in Fig. 5. Briefly, the use of the CSCs
surface markers could be used both to “recognize” CSCs as well as deliver therapeutic
agents to CSCs rather selectively. Abolishing drug efflux functionality using either low
molecular mass inhibitors of drug efflux pumps or siRNA to downregulate MDR in CSCs
can increase efficacy of conventional therapies using drug-efflux dependent therapeutic
agents. Targeting abnormal metabolism in CSCs may deplete energy in these cells and
suppress their function, by impairing their growth, inducing differentiation and, finally,
sensitizing them to the therapy. Inhibiting embryonic signaling pathways in CSCs can also
affect the life cycle of the CSCs and inhibit their tumorigenic potential. Last but not the
least, impairing the CSCs niche might deprive CSCs of an essential microenvironment that
controls their differentiation, proliferation and self-renewal. These approaches are in
different stages of development. Novel investigational agents targeting the Wnt, Notch, and
Hh pathways are currently in late preclinical development stages, and some of them are in
early phase 1–2 clinical studies. Other approaches like using drug efflux pump inhibitors in
combination with chemotherapeutic agents have been evaluated rather extensively with
relatively little success. The knowledge of CSCs and their niche microenvironments still
remains a nascent field. But all strategies to treat CSCs have serious pitfalls associated with
off target effects and high toxicity, poor bioavailability, poor cellular delivery, low efficacy
and other problems that have hindered more conventional therapeutics. Some of these
pitfalls can be addressed using drug delivery and nanomedicine approaches as discussed in
the next section.
3. Nanomedicine-based therapies against CSCs
Despite being noted as one of the most important developments in the treatment of tumor
relapse [191], nanocarrier-mediated drug delivery systems to overcome tumor drug
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resistance leave plenty of room for improvements, especially for targeting drug resistant
CSCs. Nanomedicines offer a fundamental advantage over current therapeutic agents that
are limited in use due to problems of degradation, solubility, rapid clearance from the body
and poor cellular uptake. Nanomedicines commonly display longer circulation time, higher
stability, greater bioavailability and activity. Modern nanocarriers can deliver more than one
drug and/or imaging agent at the same time. Nanoparticles can passively accumulate at the
tumor site due to enhanced permeability and retention (EPR) effect, where the drug can be
released passively or by a triggered mechanism. The surface of the nanoparticles can be
modified with targeting moieties for increased specificity and cellular uptake in target cells.
Overall, nanomedicines can serve as high-capacity carriers for therapeutic drugs and genes
or imaging agents. Additionally, nanoparticle itself can act as biological modulator or
transducer of energy to the cell surrounding, which is used for example in magnetic
hyperthermia to kill cancer cells as well as in some other approaches.
3.1 Application of nanocarriers to deliver chemotherapeutic agents to CSCs
One major application of nanocarriers is to deliver “non-druggable” molecules or existing
drugs having serious problems, such as poor solubility, stability and/or high toxicity. This
application can be useful for qualifying therapeutic agents and drug candidates that aim to
eliminate CSCs. For instance, an antibiotic salinomycin discussed above (Table 5) has
shown high potency in killing CSCs, but displayed poor aqueous solubility and severe
toxicity that hinders its clinical application. Incorporating salinomycin in nanocarrier can
address these problems. For example, Wei and colleagues conjugated salinomycin to a
hyaluronic acid-based nanogel to target CD44-positive drug resistant cells [41]. CD44
receptor is expressed at the surface of many cancer cells and it binds hyaluronic acid, which
allows to target such nanogels to CSCs [192]. This approach enhanced the bioavailability,
delivery and cytotoxic activity of salinomycin in both drug resistant cancer cell culture and
multicellular spheroids.
Nanocarriers were also used to deliver therapeutic agents that affect embryonic signaling
pathways in CSCs. As discussed above a number of these agents have been evaluated
clinically (Table 4), however, in certain cases their use was hindered by poor solubility, off-
target drug delivery and severe side effects. Recently Zhou and coauthors described a N-(2-
hydroxypropyl)methacrylamide (HPMA) conjugate of cyclopamine, a Hh pathway inhibitor,
that efficiently eliminated CD133+ cells within a prostate cancer epithelial cell line RC-92a/
hTERT [44]. Conjugation to HPMA improved the solubility of the drug and possibly
decreased its systemic toxicity. In another study Chenna and colleagues used poly(D,L-
lactide-co-glycolide) (PLGA)-PEG nanoparticles to encapsulate HPI-1, a potent antagonist
of Hh transcription factor [193]. HPI-1 has shown promise in inhibition of Hh pathway in
vitro, however, in vivo translation of this agents was hindered due to its highly lipophilic
nature and poor aqueous solubility. The nanofomulated HPI-1 (NanoHHI) had significantly
improved the systemic bioavailability compared to HPI-1 alone and showed strong
antitumor activity in vivo. NanoHHI also decreased the population of CD133+ cancer cells
and in combination with gemcitabine significantly impeded the growth of orthotopic
pancreatic and hepatocellular cancer xenografts [42].
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One important property of nanocarriers is possibility to simultaneously incorporate multiple
therapeutic agents. For example, polymeric micelles of stearate-grafted chitosan
oligosaccharide were used for co-delivery of paclitaxel and doxorubicin [194]. Another
study employed PLGA nanoparticles for simultaneous delivery of vincristine and verapamil
[195]. A liposomal delivery formulation for quercetin and vincristine was also developed
[196]. Additionally, Kwon et al. reported that PEG-block-poly(D,L-lactic acid) (PEG-b-
PLA) polymeric micelles can deliver multiple drugs including combinations of paclitaxel
and 17-allylamino-17-demethoxygeldanamycin (17-AAG), etoposide and 17-AAG,
docetaxel and 17-AAG as well as paclitaxel, etoposide and 17-AAG [197]. Most recently
Han et al. described several synergistic drug combinations in very high capacity (nearly 50
% wt/wt) poly(2-oxazoline) polymeric micelles [198]. Such multidrug combinations can act
upon multiple signaling pathways in cancer cells resulting in synergistic anticancer effect
and increased efficacy of the cancer treatment.
Likewise, the nanocarriers that combine MDR modulators and cytotoxic drugs could
simultaneously sensitize CSCs and deliver their chemotherapeutic payloads. The use of such
dual load nanocarriers may contribute to anti-CSCs therapy in future clinical trials [63].
Moreover, incorporating several MDR modulators within one nanocarrier can allow for
broad-spectrum inhibition of drug efflux transporters in CSCs. One can also use antibodies
against the drug efflux transporters to inhibit drug efflux and increase drug accumulation in
the CSCs [113]. For example, Yang and colleagues employed combination therapy of anti-
ABCG2 mAb and paclitaxel loaded iron oxide magnetic nanoparticles, coated with Pluronic
F68 against CSCs in multiple myeloma [113]. The combination therapy led to significant
reduction of tumor growth in vivo and was shown to be more effective than either the
paclitaxel, iron oxide nanoparticles or anti-ABCG2 mAb. The synergistic effect can be
explained by simultaneous inhibition of ABC transporter by antibodies and delivery of
paclitaxel to the CSCs via magnetic nanoparticles.
3.2 Application of nanocarriers to deliver nucleic acid therapeutics to CSCs
Aside from solubilization of poorly soluble drugs nanocarriers can increase stability and cell
transport of biomacromolecules, in particular, nucleic acid therapeutics that have shown
some promise for treatment of cancer [199]. Recent studies have uncovered the regulatory
role of microRNAs (miRNA) in CSCs [200] and provided rationale for using miRNAs both
as diagnostic and prognostic biomarkers of tumor progression and anti-cancer agents. For
example, recent findings suggest that miRNA-34a interferes with the viability of CSCs,
creates a barrier to metastasis, and abolishes chemoresistance by directly repressing CD44 in
pancreatic [201], gastric [202], prostate [203] and brain [204] cancers. However, miRNA-
based therapy is hampered by several challenges including lack of tissue specificity, poor
cellular uptake and risk of systemic toxicity [205]. Nanocarrier-based miRNA delivery
systems have shown clear advantages in CSCs. Thus, Shi et al. described solid lipid
nanoparticles for delivery of CD44 protein repressor miRNA-34a into CD44+ lung cancer
cells [206]. This nanocarrier not only protected miRNA from degradation, but also enhanced
the miRNA accumulation in lungs. In May 2013 Mirna Therapeutics, Inc. announced that
the first miRNA clinical study had been initiated in patients with unresectable primary liver
cancer or metastatic cancer with liver involvement (NCT01829971). In this trial MRX34, a
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liposome-formulated mimic of the tumor suppressor miRNA-34 is given to patients
intravenously two times per week for three weeks. In the pre-clinical studies, miRNA-34
mimic has shown the ability to induce the cell cycle arrest, senescence and apoptosis.
Recently, this agent was also shown to interfere with the viability of CSCs, decrease
metastases formation, and abolish chemoresistance [203].
Another interesting example is using nanocarriers for siRNA delivery to silence genes
encoding the drug efflux transporters and thereby sensitize these CSCs to chemotherapeutic
drugs. For instance, to increase stability and delivery of MDR1 silencing siRNA in MDR1-
expressing human colon CD133+ CSCs, Liu et al. used cross-linked PEI-Lipid1:16
nanoparticles [207]. The nanoformulated siRNA effectively reduced the expression of
MDR1 in CSCs, and chemosensitized these cells to paclitaxel.
Altogether, nanocarriers are of considerable interest for delivery of siRNA and other nucleic
acid based therapeutics in CSCs. However, so far much of the siRNA therapeutics using
nanocarriers (mostly lipid based nanoparticles) are limited to delivery of siRNA to the liver
as it is one organ where the systemic delivery has proven to be relatively easy. It remains to
be seen whether the nanocarrier technology can target siRNA to distal CSCs located in other
organs.
3.3 Targeting of nanocarriers to CSCs
In addition to small molecule drugs and nucleic acid-based therapeutics, antibodies have
also shown potential for eliminating CSCs. Antibodies have long been used in clinical
practice to target cancer cells and treat cancer [208, 209]. Most popular targets include
human epidermal growth factor receptor 1 (EGFR1, HER1), human epidermal growth factor
receptor 2 (EGFR2, HER2, Neu, ErbB-2, CD340, p185), membrane-spanning 4-domain
subfamily A member1 (CD20), vascular endothelial cell growth factor (VEGF) and
Interleukin-6 (IL-6). These target antigens are certainly important for cancer development
and progression, but search for new targets is still ongoing. Some of the approved and new
anti-cancer mAb and antibody constructs have shown efficacy against CSCs and induced
tumor regression in clinical trials as discussed above (Table 4).
Another application of antibodies is targeting of the therapeutic agents to CSCs. Antibody-
drug conjugates and antibody-modified nanocarriers have been explored for selective
targeting of CSCs to develop anti-CSCs therapeutics [208, 210]. Few attempts have been
made to modify the surface of nanocarriers with mAb. Since CSCs express specific cell
surface biomarkers it was natural to employ antibodies against these biomarkers for targeted
drug delivery. For example, Swaminathan et al. developed paclitaxel-loaded polymeric
PLGA nanoparticles conjugated with anti-CD133 mAb [40]. Although, the accumulation of
the targeted nanoparticles in the CD133 overexpressing Caco2 cells was 9 times higher than
that of non-targeted nanoparticles, in vitro tumorsphere and soft agar colony formation
assays in MCF7 cells has shown their similar activity. (Notably, the paclitaxel alone
increased the number of colonies formed in soft agar to 122% of untreated control.)
Nevertheless, the targeted paclitaxel-loaded nanoparticles have induced 70% tumor volume
reduction compared to untreated control in in vivo MDA-MB 231 xenograft tumor model,
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whereas the non-targeted nanoparticles or paclitaxel in Cremophor EL®/ethanol solution
resulted in 43% and 33% tumor inhibition respectively [40].
One common advantage of nanocarriers is possibility of incorporating multiple modalities in
one carrier system, allowing for delivery of either multiple therapeutic agents or imaging
and therapeutic agents at the same time. For example, Gao et al. have developed a bi-
functional nanomedicine for in vivo imaging and therapy of cancer that targeted prostate
stem cell antigen (PSCA), a cell surface antigen expressed in the CSCs. This nanomedicine
comprised PLGA nanoparticles loaded with superparamagnetic iron oxide nanoparticles
(SPIONs) and docetaxel. The surface of these nanoparticles was modified with the anti-
PSCA mAb. The targeted nanoparticles provided a negative MRI contrast enhancement and
effective tumor inhibition in vivo [211].
Despite these and some other examples all mAb-based nanomedicines targeting CSCs are in
the early preclinical development stages. One common limitation of such approaches using
mAb is potential toxicity to normal stem cells in the body. Preclinical studies used mAb
against human antigens that may not cross-react with some murine antigens. This could
mask potential systemic toxicity and other side effects in the mouse models. Moreover, the
antibodies used in preclinical and clinical studies must be very well characterized. For
instance, the use of different CD133 antibody clones that recognize different CD133 splice
variants and epitopes of different glycosylation status, has led to inconsistent results [212].
In addition to mAb, non-immunogenic synthetic “antibodies”, aptamers, are composed of
oligonucleotides or peptides, have shown potential for development of targeted CSCs
therapeutics and molecular imaging systems. For example, a CD133 specific aptamer 25–32
times smaller than mAb has shown superior tumor penetration and retention compared to
anti-CD133 antibodies in a 3-D tumorsphere model [213]. Due to their chemical versatility
aptamers can be easily conjugated to nanoparticles comprising diagnostic and/or therapeutic
agents.
However, independently of the targeting moiety one fundamental limitation of the CSCs
targeted nanocarriers could be poor extravasation and exposure of the circulating
nanocarriers to their targets. It has been shown that CSCs can localize in the necrotic areas
of the tumors, which is particularly hard to reach [214]. Therefore, the targeted nanocarrier
approaches may be more suitable to treat cancers where the CSCs are more readily
accessible, such as hematological malignancies.
3.4 Using nanoparticles to target metabolism in CSCs
Targeting metabolism in drug resistant cancers and CSCs has proven to be a challenging
task. For example, CSCs in various cancers, including breast [215, 216], leukemia [123],
gastrointestinal [217] and brain [218], are characterized by relatively low levels of ROS,
which in combination with higher DNA repair results in radioresistance of CSCs. The lower
levels of ROS are attributed to the higher content of antioxidant ROS-scavenging
compounds [217, 219]. Also, CSCs are often localized in the hypoxic areas of the tumors.
Thus, it is suggested that by enhancing tumor oxygenation it is possible to make CSCs more
susceptible to current treatments. For example, hyperthermia is used to promote tumor
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reoxygenation [220–223], radiosensitization [224] and heat shock [225, 226] in cancer cells.
However, current clinical implementations of hyperthermia have been limited due to the
nonspecific heating to the normal tissues and organs and consequent treatment-limiting side
effects [227, 228].
Several approaches using nanomedicines to enhance ROS generation and induce
morphological and functional changes and enhancement of apoptosis and necrosis in CSCs
have been investigated. In one recent example the authors designed the mitochondria
targeting PEGylated liposomes incorporating anticancer drug, daunorubicin and
mitochondrial regulator, quinacrine [229]. The liposomes displayed long circulatory effect
in vivo and selectively accumulated within the tumor sites presumably due to the EPR effect.
The mitochondrial regulator dequalinium was attached to the liposome surface to obtain the
mitochondrial targeting effect. These targeted liposomes selectively accumulated into
mitochondria which induced activation of the pro-apoptotic Bax protein, depleted the
mitochondrial membrane potential, opened the mitochondrial permeability transition pores,
released cytochrome C, and initiated a cascade of caspase 9 and 3 reactions. These effects
ultimately led to apoptosis in of MCF-7 CSCs.
Other studies have focused on killing CSCs by delivering in them the energy dissipating
magnetic nanoparticles or carbon nanotubes that are responsive to external physical fields.
For example, Sadhukha and colleagues discovered that the magnetic hyperthermia
transduced by SPION in the alternating current (AC) magnetic field can reduce CSCs
population [45]. They have shown that SPION-transduced hyperthermia decreases side
population cells, ADLH expression, tumorsphere formation, and in vivo xenotransplantation,
suggesting that magnetic hyperthermia reduced or, even eliminated the CSCs in treated
A549 and MDA-MB 231 breast cancer cells. Notably, ROS generation was increased upon
magnetic hyperthermia proportional to the time of the magnetic field exposure. At the same
time, conventional hyperthermia induced by placing the cells in the warm (46°C) water bath
did not affect the CSCs and did not induce ROS production. Interestingly ROS generation
was observed upon conventional hyperthermia in the cancer cells that were first incubated
with magnetic nanoparticles. The authors speculated that magnetic hyperthermia has
potential for lower rates of tumor recurrence compared to conventional cancer therapies.
In an earlier study by Rinaldi et al. [230] the SPION conjugated to epidermal growth factor
(EGF) were shown to target EGFR in the breast cancer cells, resulting in delivery of these
nanoparticles to lysosomes. Upon application of the AC magnetic field the EGF-targeted
SPION disrupted the lysosomal membranes, induced production of ROS and killed the
EGFR-overexpressing cancer cells but not the cancer cells with lower level of EGFR
expression [231]. Interestingly, the non-targeted SPION did not produce such strong effects
in the cancer cells. Needless to say, the nature of the cytotoxic effects of the magnetic
nanoparticles in the field is not fully understood. On one hand, it could be induced by local
dissipation of heat (local heating) in the vicinity of the SPION surface, which results in
protein denaturing and disruption cell membranes, especially in the case of the EGF-targeted
nanoparticles. On the other hand, some authors suggested that there could be induced
mechanical effect due to realignment of the magnetic nanoparticles along the field, which
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can disrupt or denature proteins and structures joining the nanoparticles and thereby affect
the cell signaling [232, 233].
Using triple-negative breast cancer model, Burke et al. recently demonstrated that breast
CSCs are markedly resistant to traditional hyperthermia and become enriched in the
surviving cell population following the treatment [234]. The mechanism may be related to
the elevated expression levels of heat shock protein 90 (HSP90) in breast CSCs. In contrast,
breast CSCs appeared to be sensitive to PEG coated multi-walled carbon nanotube-mediated
(MWCNT) thermal treatment stimulated by near infrared irradiation, and lost their long-
term proliferative capacity. Moreover, MWCNT-mediated hyperthermia promoted complete
tumor regression and long-term survival of mice with CSCs-driven breast tumors. However,
non-CSCs displayed same sensitivity to the MWCNT-mediated hyperthermia as the CSCs.
It appeared that in contrast to SPION-induced hyperthermia, which induced ROS production
in cancer cells, MWCNT-mediated hyperthermia induced critical plasma membrane
damage, which is not selective to a specific cell phenotype. Altogether the study of the
effects of electromagnetic field-responsive nanoparticles on CSCs is in its infancy but the
existing examples suggest that such effects may be of interest for developing novel anti-
CSCs therapies.
3.5 Pluronic block copolymers as multifaceted sensitizers of MDR and CSCs
Pluronic block copolymers (also known as “poloxamers”) represent a class of polymers with
triblock structure consisting of hydrophobic poly(propylene oxide) (PPO) block, flanked
from both sides with hydrophilic poly(ethylene oxide) (PEO, same as PEG) blocks (PEO-
PPO-PEO) (Fig. 6A). Pluronic micelles carrying solubilized drugs were the first polymeric
micelles reported as nanocarriers for drug delivery in animal models [235] and the first-in-
class polymeric micelle drug, which reached the clinical stage in human patients [236]. In
addition to the drug carrier function of the polymeric micelles, Pluronic molecules alone
have unique ability to chemosensitize MDR tumors by 1) inhibiting ABC transporter–
mediated drug efflux [237, 238], 2) inhibiting mitochondrial respiration and ATP synthesis
in MDR cells [239, 240], and 3) enhancing pro-apoptotic signaling in the MDR cells in
response to treatment with drug [17, 241] (Fig. 6B). The Phase II human clinical trial of
doxorubicin incorporated into mixed micelles of Pluronic F127 and L61 (SP1049C) has
shown high objective response rates (43%) and increased median survival (10 months) in
patients with inoperable metastatic adenocarcinoma of the esophagus and gastro esophageal
junction [242].
Treatment of MDR cells with doxorubicin/Pluronic formulation significantly enhanced the
pro-apoptotic signaling compared to the drug alone and inhibited the antiapoptotic defense
mechanisms in vitro [241]. Similar effects were observed in vivo [238]. It was demonstrated
that doxorubicin/Pluronic treatment of tumor-bearing mice significantly increased levels of
caspases 8 and 9 compared to doxorubicin alone. Additionally, depletion of major intrinsic
cellular antioxidant GSH would increase cell sensitivity to the ROS. Therefore when
combined with doxorubicin Pluronic not only drastically increases the drug accumulation in
the cells, but also strongly induces early, as well as late stages of proapoptotic signaling in
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MDR cells in vitro and in vivo, which in combination with the doxorubicin cytotoxic effect
results in significantly increased cell death.
One of the most important biological effects of Pluronic block copolymers is ATP depletion
in tumor cells. The copolymers that induce the strongest ATP depletion (e.g. Pluronic P85
and Pluronic L61) were also shown to be the most potent chemosensitizers of MDR cells
[243]. There is a clear correlation between the ATP depletion and chemosensitization effect
of Pluronic [244]. Moreover, both in vitro and in vivo tumor models the remarkable ATP
depletion effect of Pluronic was selective for MDR phenotype, while non-MDR cells were
not as much responsive [238]. This is supported by previous findings that modulation of
energy metabolism in drug resistant cells increases drug accumulation [245]. The reason for
Pluronic selectivity in MDR cells is uncertain, but may be in part due to differences in
energy metabolism in drug sensitive and drug resistant cells [239].
Our previous studies have shown that Pluronic reaches mitochondria and inhibits complexes
I and IV of mitochondria respiratory chain [239]. Furthermore, it stimulates the production
of ROS and release of cytochrome c, which are the early signs of mitochondrial apoptotic
pathway. Similar to ATP depletion and inhibition of respiration, Pluronic induced the ROS
formation and cytochrome c release selectively in MDR cells, while non-MDR cells did not
respond in that manner. In addition to induction of ROS production and cytochrome c
release in MDR cells, Pluronic promotes drug-induced apoptosis [241]. Inhibition of
mitochondria respiratory chain complexes is most likely the main reason for increased ROS
production in MDR cells after treatment with Pluronic.
The ability of Pluronic block copolymers to sensitize MDR tumors have been used in many
studies attempting to design a drug delivery system and overcome drug resistance in cancer.
For example Pluronic P123/F127 mixed micelles were designed for delivery of paclitaxel to
drug resistant tumors [246]. In this work the authors prepared multifunctional folate-
modified Pluronic micelles to utilize the folate-mediated endocytosis for enhanced uptake of
the micelles in combination with Pluronic ability to sensitize the MDR cells. They have
shown that these micelles significantly increase the bioavailability of paclitaxel and display
strong anti-tumor effect in drug resistant tumor xenograft model. More recently the same
group demonstrated that paclitaxel-loaded Pluronic P123/F127 mixed micelles significantly
enhanced the anti-cancer activity of paclitaxel in lung cancer resistance protein (LRP)
overexpressing human lung adenocarcinoma in vivo [247].
In another study the mixed micelles of methoxyPEG–poly(lactide) block copolymer
(MPEG–PLA or MPP) and Pluronic (L61, L62 and P85) were prepared to enhance the
stability of Pluronic micelles upon dilution in blood stream for delivery of docetaxel to
MDR tumors [248]. Pluronic significantly affected the drug loading, drug release, and
pharmacokinetic profile of these micelles, which resulted in more effective inhibition of
tumor growth and overcoming the MDR by the mixed micelles.
Pluronic block copolymers have been also used in design of drugs for oral administration as
it has been shown that selected copolymers can greatly increase permeability of multiple
drugs in intestinal cells by inhibiting the drug efflux transport systems [249]. For example
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Hosseinzadeh and co-authors have designed and characterized chitosan-Pluronic
nanoparticles for oral delivery of gemcitabine [250]. These nanoparticles have shown high
loading efficiency and good mucoadhesion properties that can be used to treat colon cancer
[250]. Moreover, it was demonstrated in another study that Pluronic P123 effectively
inhibited the Pgp efflux in intestine but had no effect on intestinal CYP450 metabolism. This
suggested that the copolymer can improve oral bioavailability of Pgp substrates without
interfering with the metabolism of the drug [251].
We have shown recently that treatment of the mice bearing the leukemia ascitic cells with
SP1049C reduces the tumor aggressiveness, in vivo tumor formation frequency and in vitro
clonogenic potential of the leukemia cells derived from the treated animals [252]. SP1049C
also prevented the overexpression of BCRP and activation of Wnt/β-catenin signaling
observed with doxorubicin alone, significantly altered the DNA methylation profiles of the
cells and decreased CD133+ cells populations, which displayed CSCs-like properties and
were more tumorigenic compared to CD133− cells [252]. Moreover in the same in vivo
leukemia ascitic cells model, the treatment of animals with Pluronic P85 and doxorubicin
prevented the development of MDR observed upon long-term treatment of the animals with
doxorubicin alone [253]. The cell culture studies also demonstrated that Pluronic P85
inhibits development of MDR in leukemia cells [253] and breast cancer cells [254] induced
by exposure of these cells to the increased concentrations of doxorubicin. This suggests that
Pluronic-based drug formulations may have potential in eliminating CSCs, thereby
providing rationale for evaluating SP1049C as an anti-CSCs agent in the clinical trials.
Pluronic block copolymers were also shown to enhance the radiofrequency ablation induced
hyperthermia in solid tumors and sensitize cancer cells to hyperthermia in vitro and in vivo
[255]. Consistent with the prior finding of the structure-functional relationships in MDR
cancer cells [243] the copolymers with lower molecular weights and hydrophilic-lipophilic
balance (HLB) < 8 demonstrated the highest thermosensitizing activity [256]. Notably, in
these Pluronics the number of PO units was even multiple of the length of 16 C-C bond
length, which is a typical length of mammalian fatty acid acyl chain. Therefore the
thermosensitization ability of Pluronic copolymer may be directly linked to its ability to
interact with plasma membrane and induce membrane fluidzation. It has been shown that the
more fluid the cell membrane becomes upon hyperthermia, the higher the cell sensitivity to
the treatment is [257]. Furthermore, in another study it was shown that Pluronic in
combination with low-grade hyperthermia depleted the intracellular ATP and decreased the
expression of heat shock protein 70 (HSP70) [258]. It is known that heat shock proteins, in
particular HSP70, increases the thermoresistance of the tumors [259]. Notably, the reduction
of HSP70 expression by Pluronic L61 was observed both in vitro and in vivo [258]. Overall,
while having relatively low inherent toxicity Pluronic block copolymers display unique
effects on cancer cells and act as potent chemo- and thermosensitizers, which have shown
clear potential to enhance anti-CSCs therapeutics.
4. Generalizations and future directions
The overview of the current state of the art suggests that there is a clear rationale and
promise in application of the nanomedicines and drug delivery technologies to develop
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novel anti-CSCs therapies. Among all different kinds of drug delivery systems, polymer-
based nanomaterials and nanocarriers are of special interest. They include polymeric
micelles, polyelectrolyte complexes with DNA, RNA, proteins and peptides, soft polymer
nanogels, solid polymer nanoparticles, polymer coated inorganic materials (including
SPION), polymer coated liposomes and others. Properly designed polymeric nanoparticles
generally have narrow size distribution, good batch to batch reproducibility and controllable
drug-release profiles [260]. Furthermore, the polymer-based nanocarriers also offer great
synthetic versatility that allows particles to be tailored for specific needs including
modification of the particle surface with targeting moieties for site-specific delivery to
cancer cells or tumor vasculature [260]. However, application of nanomedicine technologies
in anti-CSCs therapies is in a relatively early stage and along with the great promise of these
technologies many issues remain unresolved or unknown. While selected nanomedicines
have been approved clinically and more nanomedicine-based therapeutics are in human
clinical trials, to advance this technology for anti-CSCs clinical therapies more basic and
applied research is needed.
First of all, as is true for all nanoparticles that are designed to reach their target cells in the
organism, nanomedicines targeting CSCs need to penetrate to the sites where their target
cells are located. Indeed, poor extravasation of macromolecular objects with sizes exceeding
5–10 nm within interstitial spaces severely limits the ability of these objects to reach their
cellular targets within a normal tissue or tumor [261]. Hence, targeting of nanoparticles may
be restricted mainly to those sites readily accessible to the circulatory system, such as blood
components, endothelial cells, sub-endothelial structures, etc. Despite expectations
associated with the EPR effect in cancer, it is possible and even likely that in many cases
this effect will not be sufficient to reach CSCs, especially those cells located in the necrotic
sites of the tumors, or otherwise deeply embedded in their niche. This may be a paramount
limitation in cases when the nanoparticles need to come in contact and internalize in the
CSCs, such as approaches using energy dissipation from external field into the cells through
magnetic nanoparticles or carbon nanotubes, intracellular delivery of siRNA or other similar
technologies.
Another, set of problems arises in the cases when there is an intention to target nanoparticles
to the surface of the CSCs using antibodies or other targeting moieties. The concept of
targeted delivery of polymeric drug carriers to disease sites in the body is very popular and
on a surface simple. Unfortunately, it was rarely successfully realized in relevant animal
models and, to the best of our knowledge, never taken to clinic. We already discussed above
the difficulties in developing antibodies or other ligand groups that can selectively recognize
and target CSCs but not the normal stem cells or other off-target cells. Identifying good
surface markers is always an uphill battle as very few if any as such markers are available
that exhibit sufficient selectivity in the body. Moreover, as also already noted the targeted
nanomedicines must be able to reach the surfaces of the CSCs to interact with these cells
through the targeting moieties, and this is not always possible. Some nanomedicines display
elevated circulation times, which may to some extent mitigate the effect of their poor
extravasation into tissues due to increased exposure of the therapeutics in the body.
However, existing examples such as PEGylated liposomes also suggest that increased
circulation times may come at a cost of deposition of liposomes to skin resulting in skin
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toxicity effects [261]. In addition, an increase in the “cargo space” of the nanocarrier is
usually associated with an increase in the volume and surface area of this carrier. As a result,
nonspecific surface interactions of the nanocarriers with biological objects in the body (cell
surfaces, biomacromolecules, etc.) may elevate to the extent that they become comparable
with the specific binding of the targeting moieties with the receptors. At this point the
advantages of specific targeting may drop due to nonspecific binding of carriers with cells
and tissues, such as monocytes or macrophages. One obvious remedy could be, firstly, to
modify the surface of the carrier with “inert” polymer that would have minimal interactions
with the cells, and, secondly, to attach one or multiple targeting moieties at the inert layer to
allow for specific binding of the targeting moieties with their receptor. Some soft materials
like water-swollen cross-linked negatively charged block polyelectrolyte nanogels were
recently described that have very little if any detectable nonspecific binding to surfaces, yet
exhibit very good accumulation in tumors after surface modification with ligands that bind
to tumor specific-receptors [262, 263]. The problem, however, is in appropriate design of an
“inert” polymer shell that could minimize interactions of diverse nanomaterials with non-
targeted cells. The current “gold standard” of inert polymers is PEG but there are clear
indications that even this polymer attached to nanomaterials can activate complement, and
otherwise engage the body immunity [15].
Another “out-of-the-box” approach to site-specific delivery of nanomedicines that was
developed recently consists in engaging antigen presenting cells to design better therapies
[264]. It has long been known that macrophages and microglia as well as other mononuclear
phagocytes can entrap colloidal nanomaterials as exhibition of natural protective response
aimed to eliminate alien bodies from the organism. Hence, the goal of drug delivery was to
avoid or minimize such interactions. In contrast, the recent works proposed to use
immunocytes as carriers for nanoformulated drugs. In such approach, the drug nanoparticles
are engineered to maximize entrapment into the circulating immunocytes. These cells are
known to migrate to sites tissue injury, infection, or disease, where they can deliver and
release the encapsulated drug. The proof-of-concept was shown using nanosuspensions of
antiretroviral drugs [265], magnetic nanoparticles [266] polyion complex micelles
incorporating enzymes (“nanozymes”) [267] and even plasmid DNA [268]. Moreover, our
studies have shown that such cells can efficiently transfer incorporated in them nanoparticles
[269] or gene expression vectors [268] to other cells in the sites of inflammation and
disease. A possibility of targeting nanoparticles to macrophages for example through the
folate receptors with a subsequent goal of using these macrophages as “Trojan horses” to
deliver their payloads to disease sites has also been demonstrated [270]. Although this
approach has not been used so far for delivery of anticancer and anti-CSCs therapeutics, it is
seems to be promising since macrophages often comprise the CSCs niche.
The use of nanocarriers for multifaceted and combination anti-CSCs therapies is clearly in
the very beginning. Although as discussed above the conventional inhibitors of drug efflux
transporters after extensive work and clinical evaluation did not show sufficient promise, the
search for novel chemosensitizers of drug resistant cells is currently underway. In this regard
Pluronic block copolymers and in particular doxorubicin-Pluronic drug, SP1049C is of
considerable interest, due to its multiple activities in killing and preventing development of
drug resistant and metastatic cancers [18]. Notably, SP1049C is of the few so far one
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clinically evaluated nanomedicine that has also shown anti-CSCs activity. In some cases,
nanocarriers with very high capacity for drug incorporation, such as for example poly(2-
oxazoline) polymeric micelles, can be used to decrease carrier associated toxicities that are
dose limiting for some conventional formulations such as Cremophor EL®/ethanol solution
[271]. As a result the maximal tolerated dose of the reformulated nanocarrier may decrease
allowing use for treatment high drug doses that may be more efficacious in eliminating
CSCs. In other cases such carriers can allow simultaneously mixing different drugs in one
carrier particle, and this in principle can open very broad possibilities in designing
synergistic drug combinations that could affect interrelated cell signaling pathways in CSCs.
Such “drug discovery by (nano) formulation” is in early stages of its development but it
could have very far-reaching consequences. While, certain drug combinations might be
more efficient with respect to regular non-CSCs, it could not be excluded that their effect on
the CSCs might be different, for example antagonistic, and vice versa. Therefore, one should
explore how various drug combinations affect not only regular cancer cell populations, but
also CSCs.
Altogether CSCs provide an attractive target for therapy of cancers. However, targeting drug
efflux transporters, gene silencing, affecting embryonic cells pathways and metabolism in
CSCs alone will most likely not be able to provide the single “weapon”, a “magic bullet”
that will irradiate cancer. Comprehensive therapeutic agents affecting both CSCs and non-
CSCs are needed. A successful therapy also requires a thorough understanding of cross-talk
between CSCs characteristics and innate microenvironment and ability to intervene in
functioning of this environment to derail the cancer initiation, progression, resistance,
recurrence, and metastasis. In the near future, personalized therapy approaches for treating
patients based on their CSCs characterization may hold great potential to increase the
outcome of therapy and improve the quality of patients’ lives. We certainly hope that
nanomedicines will provide additional benefits for the personalized therapy and contribute
to the existing range of therapeutic modalities to safe, extend and ease life of cancer patients.
5. Conclusions
Numerous drugs and treatment regimens have emerged since 1950s when chemotherapy was
first applied to treat cancer patients. However in many cancers the treatment efficiencies of
chemotherapy have rapidly leveled off. The current success in fight against cancer has been
mostly accounted for the better screening and early detection methods rather to more
effective treatments available. In this review we summarized the current views on CSCs
models and described attempts to develop anti-CSCs therapies using conventional and
nanotechnology-based therapeutics. Understanding tumor biology is critical for the
development of successful therapies. Therefore, we focused on describing the major
properties of CSCs as possible targets for therapy development. Development of a “magic
bullet” that will eliminate CSCs within the tumor and therefore prevent the development of
drug resistance, metastasis and relapse does sound appealing. However the complexity of
the tumor organization as well as its (still) very limited understanding hinders the progress
in this direction. It is also important to realize, that every cancer is different, every patient is
different and even within the same patient primary and metastatic tumors are different and
can respond differently to the treatments. Thus, discovery and development of the
Zhao et al. Page 26






















personalized combinational therapies might be a key to successful treatments. We believe
that nanomedicine can provide unique advantages in development of such therapies.
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Fig. 1. Treatment of hierarchical tumors
(1) Treatment with most commonly used chemotherapeutic drugs (classic chemotherapy)
often results in reduction in tumor volume, but drug-resistant CSCs can survive, repopulate
the tumor and spread to distal sites (“tumor regrowth”). (2) Treatment of hierarchical
cancers with therapeutic agents that target CSCs can kill CSCs and result in tumor
remission. (3) According to the dynamic CSCs model differentiated cancer cells can reverse
their phenotype and acquire CSCs properties (“phenotype reversal”). Therefore even if
CSCs are selectively eliminated (2) the remaining cancer cells that reverse CSC phenotype
will result in the tumor regrowth. (4) Combination treatment with the CSCs targeting drugs
and conventional chemotherapies that reduce both CSCs and stromal cells may be an ideal
regimen to achieve durable response.
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Fig. 2. Schematic showing the main nanoparticles and microparticles investigated in the drug
delivery applications
Microphotograph insert presents images of PRINT® (“Particle Replication In Non-Wetting
Templates”) microparticles from the laboratory of Prof. DeSimone at the University of
North Carolina at Chapel Hill provided by his graduate students T. Shen and C. Fromen.
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Fig. 3. Clonal evolution model (A) vs. CSC model (B)
(A) Clonal evolution model is a non-hierarchical model where stochastic genetic and/or
epigenetic changes confer growth advantage as well as heritable phenotypic and functional
differences. Clones can be different in their tumorigenicity and will produce cells with
similar tumorigenic potential (e.g., Clone 1 and Clone 2). However some cells may lose
their tumorigenic capacity due to non-favorable genetic/epigenetic changes or
microenvironment (non-clonogenic cancer cells). (B) CSCs model is a hierarchical model:
(1) non tumorigenic cancer cell cannot generate new tumor; (2) CSCs have the ability to
generate a tumor, based on its self-renewal and tumorigenic properties; (3) clonal evolution
in CSCs due to genetic and/or epigenetic changes in CSCs leads to expansion of CSCs pool,
higher heterogeneity and possibly development of drug resistance; (4) recent studies
demonstrated that CSCs phenotype is dynamic and non-stem cells may acquire CSCs
properties (phenotype reversal), which eventually results in tumor recurrence.
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Fig. 4. Models of MDR development
(A) Conventional model: rare cells in the tumor have accumulated significant genetic and/or
epigenetic alterations that confer MDR. These cells will survive the chemotherapy and
proliferate in MDR tumor. (B) CSCs model: tumor contains small population of CSCs and
their differentiated progenies. The chemotherapy eliminates the differentiated cells, while
the MDR CSCs survive and produce drug resistant heterogeneous tumor, consisting of CSCs
and various differentiated (drug resistant) cells.
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Fig. 5. Possible therapeutic strategies that can eliminate CSCs
(1) Targeting cell surface proteins (for example, CD133, CD44, et al.) to develop site-
specific therapeutics against CSCs. (2) Inhibiting the drug efflux transporters to sensitize
drug resistant CSCs to chemotherapeutic agents. (3) Altering CSCs metabolism by
“reprogramming” it to “normal” status to impair growth of CSCs, induce differentiation of
CSCs and, finally, sensitize CSCs to the therapy. (4) Inhibiting cell signaling pathways that
are critical for the CSCs survival and proliferation to develop anti-CSCs therapeutic agents.
(5) Affecting the vascular niche of the CSCs to impair the specialized microenvironment
housing the CSCs.
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(A) Structure of Pluronic block copolymers along with empty and drug-loaded
polymeric micelles; and (B) schematic representation of multiple effects of Pluronic
block copolymers in MDR cells. Pluronic molecule binds with the cholesterol-rich domains
in the cell membranes (“lipid-rafts”) (1) and perturbs their structure. This results in
inhibition of the ATPase activity of the drug efflux pumps, Pgp and BCRP (2). Pluronic
translocates into mitochondria, decreases mitochondria membrane potential and inhibits
respiration (3). This leads to inhibition of the mitochondrial H+-ATPase and ATP depletion
(4). The ATP depletion (4) along with inhibition of the ATPase activity of the Pgp and
BCRP (2) results in the impairment of the drug efflux and increased accumulation of the
drug in cells (5). The interaction of Pluronic in mitochondria also releases cytochrome C,
increases ROS production, and shifts the cell signaling in response to the drug towards
apoptosis (6). The Pgp inhibition, ATP depletion, accumulation of ROS and enhanced pro-
apoptotic signaling vs. anti-apoptotic defense are usually observed in MDR cells but not in
their sensitive counterparts. Based on references [17, 18, 239].
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Table 1
Therapeutic agents reported to enrich tumors with CSCs.
Therapeutic agent or
combination treatment
CSCs detection method or
biomarker
Mechanism of tumor enrichment with
CSCs




Paclitaxel [9] Tumorsphere assay, CD44+CD24− Increased mesenchymal trans-differentiation HMLER, MCF7Ras, 4T1 In vivo tumorigenesis
assay, tumorsphere
assay
Cisplatin [10] CD133+ Activation of the Notch signaling pathway H460 and H661, human
patients
Sphere-forming assay,





Aldefluor+, ALDH1+ Activation of the Akt/β-catenin CSCs
regulatory pathway




(FEC, FAC, CMF)# [12]






















Common designations of the combination therapies: FEC: 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2
every 3 weeks; FAC: 5-fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 every 3 weeks; CMF: cyclophosphamide
600 mg/m2, methotrexate 50 mg/m2, 5-fluorouracil 500 mg/m2 every 3 weeks.
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Table 2
Models explaining cancer cell heterogeneity and possible treatment strategies.
Model Hierarchy Origin of heterogeneity Treatment strategy Example
Classical CSCs Yes Different subpopulations of cancer




Clonal evolution No Genetic, epigenetic and/or
microenvironment-driven phenotypic
changes
Elimination of all tumor
cells
High-grade B cell lymphoblastic
leukemia [75]





Melanoma [49, 80] 1
1
No specific markers identified so far that can distinguish melanoma CSCs. Melanoma tumors from patients were not hierarchically organized and
many markers appeared to be reversibly expressed by tumorigenic melanoma cells.
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Table 3
Some examples of drug efflux transporters expression in CSCs.
Drug efflux transporters CSCs biomarkers Cancer type
ABCG2 CD44+CD24− [97] Breast cancer cell lines
CD34+CD38− [96] Acute myeloid leukemia (AML) primary tissue
CD133+ [111] Human glioblastoma cell lines
CD133+ [112] Primary non-small cell lung cancer (NSCLC)
CD138−CD34− [113] Multiple myeloma
ABCB1 CD133+ [98] Glioma cells
CD133+ [10] Lung adenocarcinomas cell lines
CD133+ [114] Human hepatocellular carcinoma cells
ALDHlow [115] Human colorectal cancer
ABCB5 CD133+ [99, 100, 116] Human malignant melanoma
CD44+ [117] Oral squamous cell carcinoma specimens and cell lines
CD49f+, CD90+ [118] Nodular melanoma specimens
CD133+, Epcam+ [119] 142 clinical samples from liver tumors, adjacent non-tumorous liver tissue, and liver
tissue from patients who did not have cancer
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Table 5



























































Poor solubility [178], neural









receptor of CSCs [165]
Fatal narcoleptics malignant
syndrome [179]
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